Clinical Trials Logo

Friedreich Ataxia clinical trials

View clinical trials related to Friedreich Ataxia.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06447025 Enrolling by invitation - Friedreich Ataxia Clinical Trials

An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia

Jive
Start date: January 25, 2024
Phase: Phase 2
Study type: Interventional

This is an open-label extension (OLE) study designed to evaluate the long-term safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of subcutaneous (SC) administration of CTI-1601, also known as nomlabofusp, in subjects with Friedreich's ataxia (FRDA). The objectives of this OLE study are: - To evaluate the safety of long-term subcutaneous (SC) administration of CTI-1601 in subjects with FRDA - To evaluate the PK of long-term subcutaneous (SC) administration of CTI-1601 in subjects with FRDA - To evaluate the effect of long-term subcutaneous (SC) administration of CTI-1601 in subjects with FRDA on: - Tissue FXN concentrations - Clinical evaluations of FRDA - Gene Expression and select lipids

NCT ID: NCT05515536 Enrolling by invitation - Friedreich Ataxia Clinical Trials

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

Start date: December 8, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.

NCT ID: NCT04548921 Enrolling by invitation - Hereditary Diseases Clinical Trials

Biomarker for Friedreich's Ataxia (BioFridA)

BioFridA
Start date: July 1, 2020
Phase:
Study type: Observational

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Friedreich's Ataxia and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s